Healthcare
Trevi Therapeutics, Inc.(TRVI)
Live Price
Offline$14.21
+5.57% today
1Y Change
+147.13%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $1.97B
- Revenue Growth
- 0.0%
- EPS Growth
- +38.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trevi Therapeutics, Inc. (TRVI) is a Healthcare stock with a market cap of $1.97B and listed on NASDAQ. The stock last traded around $14.21 and up 147.1% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +38.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +38.3%, free cash flow -10.0% with operating margin 0.0% and ROIC -26.8%. Stock Foundry combines TRVI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +38.3%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -5.8% | -6.1% | -5.8% |
2026 Mar 17, 2026 | +40.0% | -4.5% | -4.9% | +27.5% |
2025 Nov 13, 2025 | +20.0% | -0.8% | -7.1% | +11.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRVI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRVI Max Drawdown
-29.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRVI and SPY.
Company Overview
Trevi Therapeutics, Inc.
NASDAQ Global Market
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
- Leadership
- Jennifer L. Good
- IPO Date
- May 7, 2019
- Employees
- 31
- Street Address
- 195 Church Street
- Mailing
- New Haven, CT, 06510
- Region
- New Haven, CT, US
- Reporting Currency
- USD
- Investor Line
- 203 304 2499
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 11.0
Growth
- Revenue
- 0.0%
- EPS
- +38.3%
- Free Cash Flow
- -10.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -25.5%
- ROIC
- -26.8%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 19.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.